Serum-free light-chain assay: Clinical utility and limitations

Annals of Clinical Biochemistry

Volumn 51, Issue 5, 2014, Pages 528-542

  Bhole, Malini V ^a   Sadler, Ross ^b   Ramasamy, Karthik ^b,c,d  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^d The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

Author keywords

analytical systems; immunoassay; Laboratory methods

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN; IMMUNOGLOBULIN LIGHT CHAIN;

ANTIGEN DETECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGY TEST KIT; INTERMETHOD COMPARISON; LATEX AGGLUTINATION TEST; LATEX AGGLUTINATION TEST KIT; LIGHT CHAIN; MONITORING; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NEPHELOMETRY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; REVIEW; RISK MANAGEMENT; SERUM FREE LIGHT CHAIN ASSAY; TREATMENT RESPONSE; URINALYSIS; URINE IMMUNOFIXATION; AMYLOIDOSIS; BLOOD; PARAPROTEINEMIAS; PHOTOMETRY; PROCEDURES;

AMYLOIDOSIS; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN LIGHT CHAINS; MULTIPLE MYELOMA; NEPHELOMETRY AND TURBIDIMETRY; PARAPROTEINEMIAS; PROGNOSIS; REFERENCE VALUES;

EID: 84906352789     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563213518758     Document Type: Review

References (90)

1. Keren DF.Procedures for the evaluation of monoclonal immunoglobulins.Arch Pathol Lab Med. 1999;123:126-132.
2. Bradwell AR,Carr-Smith HD,Mead GP, et al.Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.Clin Chem. 2001;47:673-680.
3. Medcalf EA,Newman DJ,Gorman EG, et al.Rapid, robust method for measuring low concentrations of albumin in urine.Clin Chem. 1990;36:446-449.
4. Dimopoulos M,Kyle R,Fermand JP, et al.Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.Blood. 2011;117:4701-4705.
5. Katzmann JA,Clark RJ,Abraham RS, et al.Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.Clin Chem. 2002;48:1437-1444.
6. Abraham RS,Clark RJ,Bryant SC, et al.Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma.Clin Chem. 2002;48:655-657.
7. Drayson M,Tang LX,Drew R, et al.Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.Blood. 2001;97:2900-2902.
8. Abraham RS,Katzmann JA,Clark RJ, et al.Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.Am J Clin Pathol. 2003;119:274-278.
9. Lachmann HJ,Gallimore R,Gillmore JD, et al.Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.Br J Haematol. 2003;122:78-84.
10. Brockhurst I,Harris KP,Chapman CS.Diagnosis and monitoring a case of light-chain deposition disease in the kidney using a new, sensitive immunoassay.Nephrol Dial Transplant. 2005;20:1251-1253.
11. Piehler AP,Gulbrandsen N,Kierulf P, et al.Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population.Clin Chem. 2008;54:1823-1830.
12. Katzmann JA,Kyle RA,Benson J, et al.Screening panels for detection of monoclonal gammopathies.Clin Chem. 2009;55:1517-1522.
13. Hutchison CA,Harding S,Hewins P, et al.Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease.Clin J Am Soc Nephrol. 2008;3:1684-1690.
14. Hutchison CA,Plant T,Drayson M, et al.Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.BMC Nephrol. 2008;9:11-11.
15. Abadie JM,van Hoeven KH,Wells JM.Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis?.Am J Clin Pathol. 2009;131:166-171.
16. Bradwell AR,Carr-Smith HD,Mead GP, et al.Serum test for assessment of patients with Bence Jones myeloma.Lancet. 2003;361:489-491.
17. Matsuda M,Yamada T,Gono T, et al.Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.Intern Med. 2005;44:428-433.
18. Kang SY,Suh JT,Lee HJ, et al.Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.Ann Hematol. 2005;84:588-593.
19. Holding S,Spradbery D,Hoole R, et al.Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies.Clin Chem Lab Med. 2011;49:83-88.
20. Durie BG,Harousseau JL,Miguel JS, et al.International uniform response criteria for multiple myeloma.Leukemia. 2006;20:1467-1473.
21. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
22. Dispenzieri A,Kyle R,Merlini G, et al.International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.Leukemia. 2009;23:215-24.
23. Dingli D,Kyle RA,Rajkumar SV, et al.Immunoglobulin free light chains and solitary plasmacytoma of bone.Blood. 2006;108:1979-1983.
24. Dispenzieri A,Kyle RA,Katzmann JA, et al.Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.Blood. 2008;111:785-789.
25. Rajkumar SV,Kyle RA,Therneau TM, et al.Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.Blood. 2005;106:812-817.
26. Katzmann JA,Dispenzieri A,Kyle RA, et al.Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.Mayo Clin Proc. 2006;81:1575-1578.
27. Nowrousian MR,Brandhorst D,Sammet C, et al.Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.Clin Cancer Res. 2005;11:8706-8714.
28. Beetham R,Wassell J,Wallage MJ, et al.Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?.Ann Clin Biochem. 2007;44:516-522.
29. Hill PG,Forsyth JM,Rai B, et al.Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies.Clin Chem. 2006;52:1743-1748.
30. Kyle RA,Gertz MA,Witzig TE, et al.Review of 1027 patients with newly diagnosed multiple myeloma.Mayo Clin Proc. 2003;78:21-33.
31. Landgren O,Kyle RA,Pfeiffer RM, et al.Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.Blood. 2009;113:5412-5417.
32. Weiss BM,Abadie J,Verma P, et al.A monoclonal gammopathy precedes multiple myeloma in most patients.Blood. 2009;113:5418-5422.
33. Kyle RA,Therneau TM,Rajkumar SV, et al.A long-term study of prognosis in monoclonal gammopathy of undetermined significance.N Engl J Med. 2002;346:564-569.
34. Kyle RA,Rajkumar SV.Monoclonal gammopathy of undetermined significance.Clin Lymphoma Myeloma. 2005;6:102-114.
35. Katzmann JA,Abraham RS,Dispenzieri A, et al.Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.Clin Chem. 2005;51:878-881.
36. Rajkumar SV,Kyle RA,Therneau TM, et al.Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.Br J Haematol. 2004;127:308-310.
37. Rajkumar SV,Kyle RA,Buadi FK.Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.Mayo Clin Proc. 2010;85:945-948.
38. Greipp PR,San Miguel J,Durie BG, et al.International staging system for multiple myeloma.J Clin Oncol. 2005;23:3412-3420.
39. Mead GP,Carr-Smith HD,Drayson MT, et al.Serum free light chains for monitoring multiple myeloma.Br J Haematol. 2004;126:348-354.
40. van Rhee F,Bolejack V,Hollmig K, et al.High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.Blood. 2007;110:827-832.
41. Sthaneshwar P,Nadarajan V,Maniam JA, et al.Serum free light chains: diagnostic and prognostic value in multiple myeloma.Clin Chem Lab Med. 2009;47:1101-1107.
42. Snozek CL,Katzmann JA,Kyle RA, et al.Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.Leukemia. 2008;22:1933-1937.
43. Kyrtsonis MC,Vassilakopoulos TP,Kafasi N, et al.Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.Br J Haematol. 2007;137:240-243.
44. Xu Y,Sui W,Deng S, et al.Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free kappa to lambda light chains.Leuk Lymphoma. 2013;54:123-132.
45. Maltezas D,Dimopoulos MA,Katodritou I, et al.Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.Hematol Oncol. 2013;31:356-362.
46. Dispenzieri A,Lacy MQ,Katzmann JA, et al.Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.Blood. 2006;107:3378-3383.
47. Kumar S,Dispenzieri A,Katzmann JA, et al.Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.Blood. 2010;116:5126-5129.
48. Kumar S,Dispenzieri A,Lacy MQ, et al.Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.J Clin Oncol. 2012;30:989-995.
49. Palladini G,Dispenzieri A,Gertz MA, et al.New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.J Clin Oncol. 2012;30:4541-4549.
50. Bird JM,Owen RG,D'Sa S, et al.Guidelines for the diagnosis and management of multiple myeloma 2011.Br J Haematol. 2011;154:32-75.
51. Alexanian R,Haut A,Khan AU, et al.Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.JAMA. 1969;208:1680-1685.
52. Richardson PG,Weller E,Lonial S, et al.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Blood. 2010;116:679-686.
53. Jakubowiak AJ,Dytfeld D,Griffith KA, et al.A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.Blood. 2012;120:1801-1809.
54. Augustson BM,Begum G,Dunn JA, et al.Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party.J Clin Oncol. 2005;23:9219-9226.
55. Ying WZ,Wang PX,Aaron KJ, et al.Immunoglobulin light chains activate nuclear factor-kappaB in renal epithelial cells through a Src-dependent mechanism.Blood. 2011;117:1301-1307.
56. Hutchison CA,Heyne N,Airia P, et al.Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.Nephrol Dial Transplant. 2012;27:3823-3828.
57. Dimopoulos MA,Roussou M,Gkotzamanidou M, et al.The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.Leukemia. 2013;27:423-429.
58. Gertz MA.The classification and typing of amyloid deposits.Am J Clin Pathol. 2004;121:787-789.
59. Sanchorawala V,Seldin DC,Magnani B, et al.Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.Bone Marrow Transplant. 2005;36:597-600.
60. Itzykson R,Le Garff-Tavernier M,Katsahian S, et al.Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia.Haematologica. 2008;93:793-794.
61. Leleu X,Xie W,Bagshaw M, et al.The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.Clin Cancer Res. 2011;17:3013-3018.
62. Dawson MA,Patil S,Spencer A.Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains.Haematologica. 2007;92:143-144.
63. Qu X,Zhang L,Fu W, et al.An infrequent relapse of multiple myeloma predominantly manifesting as light chain escape: clinical experience from two Chinese centers.Leuk Lymphoma. 2010;51:1844-1849.
64. Egan JB,Shi CX,Tembe W, et al.Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.Blood. 2012;120:1060-1066.
65. Pratt G,Harding S,Holder R, et al.Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia.Br J Haematol. 2009;144:217-222.
66. Maurer MJ,Cerhan JR,Katzmann JA, et al.Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.Blood. 2011;118:2821-2826.
67. Maurer MJ,Micallef IN,Cerhan JR, et al.Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.J Clin Oncol. 2011;29:1620-1626.
68. Landgren O,Goedert JJ,Rabkin CS, et al.Circulating serum free light chains as predictive markers of AIDS-related lymphoma.J Clin Oncol. 2010;28:773-779.
69. Thompson CA,Maurer MJ,Cerhan JR, et al.Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.Am J Hematol. 2011;86:998-1000.
70. Pardanani A,Lasho TL,Finke CM, et al.Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.J Clin Oncol. 2012;30:1087-1094.
71. te Velthuis H,Knop I,Stam P, et al.N Latex FLC - new monoclonal high-performance assays for the determination of free light chain kappa and lambda.Clin Chem Lab Med. 2011;49:1323-1332.
72. Tate J,Ward G.Interferences in immunoassay.Clin Biochem Rev. 2004;25:105-120.
73. Daval S,Tridon A,Mazeron N, et al.Risk of antigen excess in serum free light chain measurements.Clin Chem. 2007;53:1985-1986.
74. McCudden CR,Voorhees PM,Hammett-Stabler CA.A case of hook effect in the serum free light chain assay using the Olympus AU400e.Clin Biochem. 2009;42:121-124.
75. Murata K,Clark RJ,Lockington KS, et al.Sharply increased serum free light-chain concentrations after treatment for multiple myeloma.Clin Chem. 2010;56:16-18.
76. Jenner E,Levoguer A,Evans J, et al.Serum free light chain immunoassays: a guide to antigen excess detection.Clin Chim Acta. 2012;413:949; author reply 52-949; author reply 52.
77. Tate J,Bazeley S,Sykes S, et al.Quantitative serum free light chain assay - analytical issues.Clin Biochem Rev. 2009;30:131-140.
78. Bosmann M,Kossler J,Stolz H, et al.Detection of serum free light chains: the problem with antigen excess.Clin Chem Lab Med. 2010;48 (10): 1419-1422.
79. Levinson SS.Hook effect with lambda free light chain in serum free light chain assay.Clin Chim Acta. 2010;411:1834-1836.
80. Vercammen M,Meirlaen P,Broodtaerts L, et al.Effect of sample dilution on serum free light chain concentration by immunonephelometric assay.Clin Chim Acta. 2011;412:1798-1804.
81. Murng SH,Follows L,Whitfield P, et al.Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.Clin Exp Immunol. 2013;171:201-209.
82. Lock R,Saleem R,Roberts E, et al.A multicentre study comparing two methods for serum free light chain analysis.Ann Clin Biochem. 2013;50:255-261.
83. Tate JR,Mollee P,Dimeski G, et al.Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.Clin Chim Acta. 2007;376:30-36.
84. Briand PY,Decaux O,Caillon H, et al.Analytical performance of the serum free light chain assay.Clin Chem Lab Med. 2010;48:73-79.
85. Dispenzieri A,Zhang L,Katzmann JA, et al.Appraisal of immunoglobulin free light chain as a marker of response.Blood. 2008;111:4908-4915.
86. Gertz MA,Comenzo R,Falk RH, et al.Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.Am J Hematol. 2005;79:319-328.
87. de Kat Angelino CM,Raymakers R, et al.Overestimation of serum kappa free light chain concentration by immunonephelometry.Clin Chem. 2010;56:1188-1190.
88. Hoedemakers RM,Pruijt JF,Hol S, et al.Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis.Clin Chem Lab Med. 2012;50:489-495.
89. Pretorius CJ,Klingberg S,Tate J, et al.Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots.Ann Clin Biochem. 2012;49:450-455.
90. Basu S,Wallage MJ,Lock RJ.Response to Pretorius: 'Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser'.Ann Clin Biochem. 2013;50:278-279.